Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Stock Chart & Stats
$177.27
-$0.23(-0.27%)
At close: 4:00 PM EST
$177.27
-$0.23(-0.27%)
Day’s Range― - ―
52-Week Range$86.99 - $184.40
Previous CloseN/A
Volume140.83K
Average Volume (3M)655.67K
Market Cap
$8.94B
Enterprise Value$5.97B
Total Cash (Recent Filing)$325.27M
Total Debt (Recent Filing)$218.60M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 02, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding50,412,640
10 Day Avg. Volume860,283
30 Day Avg. Volume655,672
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)71.10
Price to Sales (P/S)10.51
P/FCF Ratio-31.50
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue10.63
Enterprise Value/Gross Profit11.58
Enterprise Value/Ebitda-28.11
Forecast
1Y Price Target
$204.00Price Target Upside15.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)0.56
Revenue Forecast (FY)$1.00B
Bulls Say, Bears Say
Bulls Say
Commercial MomentumAuvelity and Sunosi sales beating expectations and rising prescription trends point to improving commercial execution that may drive stronger revenue growth and raise analyst expectations.
Pipeline DiversificationAcquiring global rights to AZD7325 (to be developed as AXS-17) brings a clinically characterized candidate into the portfolio at modest cost, supporting pipeline diversification into epilepsy with limited near‑term capital demands.
Regulatory Approval ProspectsFDA acceptance of the supplemental NDA for AXS-05 with Priority Review and Breakthrough Therapy Designation increases the likelihood of label expansion into Alzheimer's disease agitation, which could significantly expand the addressable market for the product.
Bears Say
Clinical Trial UncertaintyThe ADVANCE-2 study for AXS-05 missing its primary endpoint highlights inconsistency in clinical results and increases uncertainty around regulatory outcomes and commercial positioning.
Drug Development ComplexityChallenges in dialing out α1 subunit affinity while retaining efficacy underscore scientific difficulty in creating a truly non‑sedative benzodiazepine alternative, raising technical and regulatory risk for similar programs.
Product Launch UptakeSymbravo's weak new prescription uptake and volatile prescription patterns indicate slower initial adoption that could constrain early sales momentum for the migraine franchise.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $86.99 and its highest was $184.40 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $8.94B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 42 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Nov 03, 2025. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.861 by -$0.079.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -0.72.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 50,412,640 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.861. Following the earnings report the stock price went up 0.563%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$204.00 (15.08% Upside)
$204.00 (15.08% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.20%
12-Months-Change
Fundamentals
Return on Equity
-275.50%
Trailing 12-Months
Asset Growth
19.20%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
AXSM Company Deck
AXSM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Axsome Therapeutics reported strong revenue growth and product performance, supported by strategic commercial execution and a robust R&D pipeline. However, increased expenses and ongoing net losses present financial challenges.View all AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$204.00
▲(15.08% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
15.70% Insiders
23.40% Mutual Funds
1.05% Other Institutional Investors
46.86% Public Companies and Individual Investors